Boston Pharmaceuticals
-
Upper Providence’s GSK Bets Big on ‘Game-Changing’ Liver Disease Drug
GSK has announced a $1.2 billion deal to acquire efimosfermin alfa from Boston Pharmaceuticals, writes John George for the Philadelphia…
Founding Partners
Advertisement
Affiliate Partners
Community Partners
